Cited by 235Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsUltrasound and Hyperthermia Applications

Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells

Lv, Yaqi, Xu, Chaoran, Zhao, Xiangmei, Lin, Chenshi, Yang, Xin, Xin, Xiaofei, Zhang, Li, Qin, Chao +4 more·2018·ACS Nano

Abstract

The tumor microenvironment (TME) plays a critical role in tumor initiation, progression, invasion, and metastasis. Therefore, a therapy that combines chemotherapeutic drugs with a TME modulator could be a promising route for cancer treatment. This paper reports a nanoplatform self-assembled from a hyaluronic acid (HA)-paclitaxel (PTX) (HA-PTX) prodrug and marimastat (MATT)-loaded thermosensitive liposomes (LTSLs) (MATT-LTSLs) for the dual targeting of the TME and cancer cells. Interestingly, the prodrug HA-PTX can self-assemble on both positively and negatively charged liposomes, forming hybrid nanoparticles (HNPs, 100 nm). Triggered by mild hyperthermia, HA-PTX/MATT-LTSLs HNPs rapidly release their payloads into the extracellular environment, and the released HA-PTX quickly enters 4T1 cells through a CD44-HA affinity. The HNPs possess promoted tumor accumulation (1.6-fold), exhibit deep tumor penetration, and significantly inhibit the tumor growth (10-fold), metastasis (100%), and angiogenesis (10-fold). Importantly, by targeting the TME and maintaining its integrity via inhibiting the expression and activity of matrix metalloproteinases (>5-fold), blocking the fibroblast activation by downregulating the TGF-β1 expression (5-fold) and suppressing the degradation of extracellular matrix, the HNPs allow for significant metastasis inhibition. Overall, these findings indicate that a prodrug of an HA-hydrophobic-active compound and liposomes can be self-assembled into a smart nanoplatform for the dual targeting of the TME and tumor cells and efficient combined treatment; additionally, the co-delivery of MATT and HA-PTX with the HNPs is a promising approach for the treatment of metastatic cancer. This study creates opportunities for fabricating multifunctional nanodevices and offers an efficient strategy for disease therapy.

Integrity signals

Registry

Crossref · 10.1021/acsnano.7b08051

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Integration of TME-targeting with HA-based nanodrugs with a TME regulator is a prospective approach for cancer therapy.

    “The study showed that the integration of TME-targeting with HA-based nanodrugs with a TME regulator is a prospective approach for cancer therapy [53].”
  • A thermo-responsive HA-based nanosystem for codelivery of MMP inhibitor marimastat and paclitaxel conjugated with HA fostered accumulation of drugs into tumors, demonstrating tumor inhibition and metastasis inhibition.

    “A thermo-responsive self-assembled HA-based nanosystem for codelivery of MMP (matrix metalloproteinase) inhibitor (marimastat) and paclitaxel conjugated with HA was fabricated for duple targeting of TME and tumor cells. The developed nanoplatform fostered the accumulation of drugs into tumors, demonstrating tumor inhibition, and metastasis inhibition.”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., He, W., & Yin, L.
Affiliations
China Pharmaceutical University (CN)
Corresponding author
  • He, Wei
  • Yin, Lifang
Venue
ACS Nano
Published
2018-01-24
Volume
12
Issue
2
Pages
1519-1536
ISSN
  • 1936-0851 (ISSN-L)
  • 1936-086X
OpenAlex
W2782822015
Cited by
235
References
69
Citations by year
2026: 10 · 2025: 15 · 2024: 17 · 2023: 25 · 2022: 38 · 2021: 41 · 2020: 39 · 2019: 32 · 2018: 18
FWCI
10.51
Type
journal article
Language
en
Open access
closed
Locations
  • ACS Nano (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education of the People's Republic of China
  • Natural Science Foundation of Jiangsu Province (BK20140671)
  • Government of Jiangsu Province
  • National Natural Science Foundation of China (81402869, 81473152)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Keywords
tumor microenvironment targeting, CD44, hyaluronic acid, paclitaxel prodrug, marimastat, thermosensitive liposomes, hybrid nanostructures, metastasis suppression, matrix metalloproteinase inhibition, TGF-β1, extracellular matrix degradation, 4T1 cells, tumor angiogenesis
MeSH terms
Animals, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Delayed-Action Preparations, Enzyme Inhibitors, Humans, Hyaluronic Acid, Hydroxamic Acids, Liposomes, Mice, Inbred BALB C, Prodrugs, Drug Delivery Systems, Paclitaxel, Hyaluronan Receptors, Cell Line, Tumor, Tumor Microenvironment, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review